Myeloproliferative neoplasm classification

Myeloproliferative Neoplasm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating myeloproliferative neoplasm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myeloproliferative neoplasm classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myeloproliferative neoplasm classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myeloproliferative neoplasm classification
on Myeloproliferative neoplasm classification
Myeloproliferative neoplasm classification in the news
Blogs on Myeloproliferative neoplasm classification
Directions to Hospitals Treating Myeloproliferative neoplasm
Risk calculators and risk factors for Myeloproliferative neoplasm classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Myeloproliferative neoplasm may be classified according to the World Health Organization into eight subtypes: polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myelogenous leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, myeloproliferative neoplasms unclassifiable, and mastocytosis. Each subtypes is based on a distinct malignant cell, and each subtype has different criteria for diagnosis.

Classification

Disease	Cell of origin	W.H.O. Diagnostic criteria
Polycythemia vera	Erythroid precursor	Major criteria: Hemoglobin > 16.5 g/dl in men or hemoglobin > 16 g/dl in women Bone marrow biopsy showing hypercellularity for age and trilineage growth (panmyelosis) Presence of JAK2 V617F or exon 12 mutation Minor criterion: Subnormal erythropoietin level Diagnosis requires meeting all 3 major criterion or the top 2 major plus the 1 minor criterion
Essential thrombocythemia	Megakaryocyte	Major criteria: Platelet count > 450,000 per microliter Bone marrow biopsy showing mainly the proliferation of megakaryocytes with increased number of enlarged and mature megakaryocytes Not meeting criteria for other myeloproliferative neoplasms Presence of JAK2, CALR, or MPL mutation Minor criterion: Presence of a clonal marker or absence of reactive thrombocytosis Diagnosis requires meeting all 4 major criteria or the first 3 major plus the 1 minor criterion.
Primary myelofibrosis	Megakaryocyte	Major criteria: Presence of megakaryocyte proliferation and atypia with reticulin fibrosis Not meeting criteria for other myeloproliferative neoplasms Presence of JAK2, CALR, or MPL mutation Minor criteria: Anemia White blood cell count >11,000 per microliter. Palpable splenomegaly Elevated LDH Leukoerythroblastic smear Diagnosis requires meeting all major criteria and at least 1 minor criterion.
Chronic myeloid leukemia	Common myeloid progenitor	Presence of BCR-ABL translocation (chromosomes 9 and 22)
Chronic neutrophilic leukemia	Neutrophil	Peripheral blood white blood cell count > 25,000 per microliter with rare myeloblasts and no dysgranulopoiesis Bone marrow hypercellularity with increased granulocytes and normal maturation and <5% myeloblasts Not meeting criteria for other myeloproliferative neoplasms Absence of genetic rearrangements of PDGFRA, PDGFRB, FGFR1, or PCM1-JAK2 Presence of CSF3R T618I or other characteristic mutation
Chronic eosinophilic leukemia	Eosinophil	No formal W.H.O. criteria Typically associated with >1,500 eosinophils per microliter in peripheral blood Typically associated with rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2
Myeloproliferative neoplasm, unclassifiable	Variable	Not meeting criteria for other subcategories
Mastocytosis	Mast cell	Major criteria: Dense multifocal aggregates of >15 mast cells in bone marrow or other organ Minor criteria: Presence of c-kit D816Vmutation Expression of CD2, CD25, or both on mast cells Serum tryptase level >20ng/ml when patient is at baseline health Atypical morphology or spindles in >25% of mast cells in bone marrow or other organ Diagnosis requires meeting the one major plus one minor criterion, or 3 minor criteria.